UnitedHealth Group (UNH) received a Bank of America price target raise to $337 from $315 after the Centers for Medicare & Medicaid Services finalized 2027 Medicare Advantage rates at a 2.48% increase, exceeding the expected 1% to 2% improvement and delivering $13 billion in total industry gains. Humana (HUM) also saw its target raised to $210 from $196, Elevance Health (ELV) to $405 from $385, and Molina Healthcare (MOH) to $152 from $145.
CMS’s Medicare Advantage rate finalization provides managed care insurers with clearer visibility into 2027 profitability and cost recovery, allowing them to price products more confidently after absorbing cost trends that outpaced pricing assumptions in 2025.
If you’re focused on picking the right stocks and ETFs you may be missing the bigger picture: retirement income. That is exactly what The Definitive Guide to Retirement Income was created to solve, and it’s free today. Read more here
UnitedHealth Group (NYSE:UNH) stock got a meaningful vote of confidence from Bank of America on Tuesday, as analyst Kevin Fischbeck raised the firm’s price target to $337 from $315 following a key Medicare Advantage policy update. BofA keeps a Neutral rating on the shares, so the revised target reflects a materially improved policy backdrop for managed care.
The Centers for Medicare & Medicaid Services finalized Medicare Advantage rates for 2027, delivering a net increase of 2.48% that came in above the high end of the 1% to 2% improvement versus the proposal that the market was expecting. The total dollar impact across the industry amounts to $13 billion, covering 35 million Medicare Advantage enrollees.
Ticker
Company
Firm
Action
Old Rating
New Rating
Old Target
New Target
UNH
UnitedHealth Group
Bank of America
Price Target Raised
Neutral
Neutral
$315
$337
BofA raised price targets across several managed care names, citing higher multiples after CMS finalized Medicare Advantage rates, as the rule provides visibility on 2027 rates. The finalized rate increase exceeded expectations, giving insurers a clearer runway to price products profitably going into next year. That visibility matters for a company like UnitedHealth, which spent much of 2025 absorbing cost trends that outpaced pricing assumptions.
If you’re focused on picking the right stocks and ETFs you may be missing the bigger picture: retirement income. That is exactly what The Definitive Guide to Retirement Income was created to solve, and it’s free today. Read more here
Story Continues
BofA wasn’t alone in revising its managed care outlook. The firm also raised its target on Humana (NYSE:HUM) to $210 from $196 (Neutral), Elevance Health (NYSE:ELV) to $405 from $385 (Neutral), and Molina Healthcare (NYSE:MOH) to $152 from $145 (Underperform).
UnitedHealth Group is one of the largest health insurers in the U.S., operating through UnitedHealthcare on the insurance side and Optum Health, Optum Insight, and Optum Rx on the services side. Full-year 2025 revenue came in at $447.57 billion, up 11.81% year over year, though operating income fell 41.26% as the medical care ratio climbed to 88.9%. The company is now deliberately shrinking its membership base, planning to exit 2.3 to 2.8 million members from unprofitable contracts in 2026.
UnitedHealth shares are up 8% this morning, but they previously had a rough stretch. The stock is still down 8% year to date and has declined 42% over the past year, with shares currently trading around $305. The CMS rate finalization gives the company a more predictable cost-recovery framework heading into 2027 — exactly the kind of clarity that can stabilize a beaten-down stock. Management’s 2026 adjusted EPS guidance calls for more than $17.75, signaling a recovery from the pressures that defined last year.
The forward P/E ratio sits at roughly 16x, well below the trailing multiple, suggesting the market is already pricing in a meaningful earnings rebound. The analyst consensus average price target stands at $357.81, making BofA’s $337 target one of the more conservative reads on the street.
If you’re a long-term investor watching UnitedHealth stock, the CMS rate finalization removes one significant overhang. The BofA price target raise reflects improved visibility, not a fundamental turnaround call, and the Neutral rating is a reminder that execution risk remains real. Watch for whether Q1 2026 earnings, expected April 21, show the medical cost ratio continuing to stabilize before drawing stronger conclusions.
The sector-wide nature of BofA’s upgrades signals a policy-driven re-rating, not a company-specific catalyst — meaningful context for anyone weighing managed care exposure in a retirement portfolio right now.
Most investors spend years learning how to pick good stocks and funds. Far fewer have a clear plan for turning those investments into a reliable retirement paycheck. The truth is, the transition from “building wealth” to “living on wealth” is one of the most overlooked risks facing successful investors in their 50s, 60s and 70s.
That is exactly what The Definitive Guide to Retirement Income was created to solve. It’s a free guide that outlines the straightforward math and strategies you need to convert your investments to income. Learn more here.